Fezolinetant: First Approval
This article summarizes the milestones in the development of fezolinetant leading to this first approval in this indication. (Source: Drugs)
Source: Drugs - July 18, 2023 Category: Drugs & Pharmacology Source Type: research
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study
ConclusionsOmalizumab showed a marked OC-sparing capacity and was associated with an improvement in clinical management that correlated with bronchial epithelial repair. In OC-dependent asthma, reversibility of remodelling is possible; the concepts that basement membrane enlargement is detrimental and that chronic airway obstruction is systematically irreversible are outdated (EudraCT: 2009-010914-31). (Source: Drugs)
Source: Drugs - July 12, 2023 Category: Drugs & Pharmacology Source Type: research
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study
ConclusionA significant increase in the risk of ACD was observed in the population-level cohort of individuals treated with DAAs, regardless of the regimen. Further research is needed to identify patients at risk of ACD, determine cardiac monitoring strategies, and evaluate the need for Holter monitoring after DAA therapy. (Source: Drugs)
Source: Drugs - July 12, 2023 Category: Drugs & Pharmacology Source Type: research
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study
ConclusionsOmalizumab showed a marked OC-sparing capacity and was associated with an improvement in clinical management that correlated with bronchial epithelial repair. In OC-dependent asthma, reversibility of remodelling is possible; the concepts that basement membrane enlargement is detrimental and that chronic airway obstruction is systematically irreversible are outdated (EudraCT: 2009-010914-31). (Source: Drugs)
Source: Drugs - July 12, 2023 Category: Drugs & Pharmacology Source Type: research
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study
ConclusionA significant increase in the risk of ACD was observed in the population-level cohort of individuals treated with DAAs, regardless of the regimen. Further research is needed to identify patients at risk of ACD, determine cardiac monitoring strategies, and evaluate the need for Holter monitoring after DAA therapy. (Source: Drugs)
Source: Drugs - July 12, 2023 Category: Drugs & Pharmacology Source Type: research
Beremagene Geperpavec: First Approval
This article summarizes the milestones in the development of beremagene geperpavec leading to this first approval for dystrophic epidermolysis bullosa. (Source: Drugs)
Source: Drugs - July 11, 2023 Category: Drugs & Pharmacology Source Type: research
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management
AbstractPost-pancreatitis diabetes mellitus, pancreatic cancer-related diabetes, and cystic fibrosis-related diabetes are often underappreciated. As a result, a substantial proportion of people with these sub-types of diabetes receive antidiabetic medications that may be suboptimal, if not harmful, in the context of their underlying disease of the exocrine pancreas. The present article delineates both classical (biguanides, insulin, sulfonylureas, α-glucosidase inhibitors, thiazolidinediones, and meglitinides) and newer (glucagon-like peptide-1 receptor agonists, amylin analogs, dipeptidyl peptidase-4 inhibitors, sodium-g...
Source: Drugs - July 6, 2023 Category: Drugs & Pharmacology Source Type: research
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
AbstractHepatocellular carcinoma (HCC) is a leading cause of cancer death globally and is rising in incidence. Until recently, treatment options for patients with advanced stages of HCC have been limited to antiangiogenic therapies with modest improvements in overall survival. The emerging role of immunotherapy with immune checkpoint inhibitors (ICI) in oncology has led to a rapid expansion in treatment options and improvements in outcomes for patients with advanced stages of HCC. Recent clinical trials have shown meaningful survival improvement in patients treated with the combination of bevacizumab and atezolizumab, as w...
Source: Drugs - July 4, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
(Source: Drugs)
Source: Drugs - July 1, 2023 Category: Drugs & Pharmacology Source Type: research
